{"id":"NCT00756002","sponsor":"Takeda","briefTitle":"Safety and Efficacy Study of Ramelteon in Subjects With Chronic Insomnia","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, Polysomnography Plus Outpatient Study to Determine the Safety and Efficacy of 4 mg Ramelteon in Adults With Chronic Insomnia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-08","primaryCompletion":"2008-03","completion":"2008-03","firstPosted":"2008-09-19","resultsPosted":"2009-11-05","lastUpdate":"2010-06-02"},"enrollment":259,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Sleep Initiation and Maintenance Disorders"],"interventions":[{"type":"DRUG","name":"Ramelteon","otherNames":["Rozeremâ„¢","TAK-375"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Ramelteon 4 mg QD","type":"EXPERIMENTAL"},{"label":"Placebo QD","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine the safety and efficacy of 4 mg of Ramelteon, once daily (QD), in subjects with chronic insomnia.","primaryOutcome":{"measure":"Mean Latency to Persistent Sleep Via Polysomnography (Nights 1-2).","timeFrame":"Nights 1-2","effectByArm":[{"arm":"Placebo QD","deltaMin":67,"sd":2.88},{"arm":"Ramelteon 4 mg QD","deltaMin":41.7,"sd":2.83}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":15,"exclusionCount":17},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":["http://general.takedapharm.com/content/file/pi.pdf?applicationcode=ab2d7112-8eb3-465a-8fda-35018a9eafb0&fileTypeCode=ROZEREMPI"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":129},"commonTop":["Headache","Nasopharyngitis","Somnolence","Dizziness","Diarrhoea"]}}